Pharmacogenomics
Information on pharmacogenomics, including pharmacogenomic information in centrally authorised medicines and scientific guidelines for medicine developers.
Finnish is available via eTranslation, the European Commission's machine translation service.
Translate to Finnish | Important information about machine translation
Pharmacogenomics (PGx) studies how genetic variation may influence a person's response to medicines. This includes how well a medicine works, its safety, and how the body processes it.
Where the evidence is sufficiently established and clinically relevant, pharmacogenomic information may help inform the choice of a medicine or dose.
Pharmacogenomic information may include details on genetic variations and biomarkers that can influence medicine response.
In the European Union (EU), the summary of product characteristics (SmPC) is the authoritative product information for healthcare professionals.
Pharmacogenomic information may appear in different sections of the SmPC. These sections include indications, posology, contraindications, warnings and precautions, interactions, undesirable effects and pharmacological properties.
The table below lists centrally authorised medicines that contain pharmacogenomic information in their summaries of product characteristics (SmPC).
It is intended to help users identify whether a medicine contains pharmacogenomic information and, if so, where that information is located within the SmPC.
It focuses on pharmacogenomic biomarkers and other genetic factors that may influence:
- Choice of medicine
- Dosing recommendations
- Treatment effectiveness
- Risk of side effects
- How the body processes a medicine
The table includes:
- Inherited genetic variations
- Relevant acquired (somatic) genetic variations
- Recognised metaboliser types
The table does not include:
- Medicine interactions that do not involve genetic variation
- References to proteins or enzymes that are not linked to genetic differences in medicine response
- Biomarkers assessed only through non-genetic tests
For each entry, the table provides the medicine name, active substance, gene name and HGNC symbol, relevant section of the SmPC and a link to the medicine page on this website.
The date of the most recent update is indicated next to and within the table.
The inclusion of a medicine in the table does not mean that genetic testing is necessary or appropriate for every patient.
Healthcare professionals should consult the full SmPC and consider the information in the context of each patient's care. Patients should speak to a healthcare professional if they have questions about their medicine or genetic testing.
EMA started publishing this table in September 2026. This in line with the Network Data Steering Group workplan 2026-28. It also follows recommendations from the Joint European Commission / Heads of Medicines Agencies / EMA multi-stakeholder workshop on pharmacogenomics held in2024.
Scientific guidelines
Scientific guidelines are available to help medicine developers on matters related to pharmacogenomics.
This includes recommendations on the design and conduct of clinical trials.
For more information, see:
Page update history
An update log is available to show the date and summary of changes to this webpage. It does not include updates to linked documents or minor edits like typos or broken link fixes.
The tracking of updates begins in September 2026.
4 September 2026
Page first published